Tevogen Inc. $TVGN

By Microcap Ledger desk · CIK 0001860871

Facts as of Oct 11, 2026, 08:13 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Global Market
Sector: Biological Products, (No Diagnostic Substances)
Headquarters: Warren, NJ
Fiscal year end: December 31
Shares outstanding: 6,511,540 [10-Q 2026-08-14]
as of 2026-08-10

Sources: [10-K 2026-03-31]

What the company doesAI summary of filing

Tevogen Inc. is a clinical-stage company developing off-the-shelf, allogeneic CD8+ T cell therapies for infectious diseases, cancers, and other disorders using its proprietary ExacTcell technology platform. The company's lead product candidate, TVGN 489, completed a Phase 1 proof-of-concept trial in January 2023 for treatment of high-risk COVID-19 patients, showing safety and rapid viral load reduction, with plans to advance to pivotal trials in COVID-19 patients with B cell malignancies and for Long COVID. Tevogen is pre-revenue and developing a pipeline of additional T cell therapy candidates leveraging ExacTcell across infectious disease and oncology indications. [10-K 2026-03-31]

Segments: TVGN 489 (COVID-19 and Long COVID), ExacTcell technology platform

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$11.21M	−$5.74M	$1.08M	[10-Q 2026-08-14]
FY ended Dec 2025	—	−$26.28M	−$12.33M	$0.00	[10-K 2026-03-31]
FY ended Dec 2024	—	−$13.73M	−$12.00M	$0.00	[10-K 2026-03-31]

Quarterly cash burn: −$2.87M
Cash runway Estimate: ~1.1 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2025-03-21	183,893,433	[10-K 2025-04-02]
2025-05-13	183,893,433	[10-Q 2025-05-14]
2025-08-13	196,705,067	[10-Q 2025-08-14]
2025-11-12	198,689,921	[10-Q 2025-11-14]
2026-03-27	4,164,205	[10-K 2026-03-31]
2026-04-28	4,187,505	[10-K/A 2026-04-30]
2026-05-12	4,187,505	[10-Q 2026-05-15]
2026-08-10	6,511,540	[10-Q 2026-08-14]

Shelf registration: S-3 filed 2026-06-12; declared effective 2026-06-25 [S-3 2026-06-12]

Listing status

Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-04-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-04-22	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-04-22]
2025-09-26	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-09-26]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-09-14	Saadi Ryan H.	grant	8,000,000	—	[4 2026-09-16]
2026-09-14	Desai Kirti	grant	750,000	—	[4 2026-09-16]
2026-09-11	Goh Keow Lin	grant	75,000	—	[4 2026-09-15]
2026-09-11	Podlogar Susan M	grant	75,000	—	[4 2026-09-15]
2026-09-11	Sordillo Victor J.	grant	75,000	—	[4 2026-09-15]
2026-09-11	Feike Jeffrey L.	grant	75,000	—	[4 2026-09-15]
2026-09-11	Patton Curtis L.	grant	75,000	—	[4 2026-09-15]
2026-07-10	Sordillo Victor J.	grant	40,000	—	[4 2026-07-10]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-30	8-K	Other events
2026-09-16	13D/A	Beneficial ownership report (5%+ holder)
2026-09-16	13D/A	Beneficial ownership report (5%+ holder)
2026-09-16	8-K	Director or officer change
2026-09-10	8-K	Other events
2026-08-26	8-K	Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results
2026-08-14	10-Q	Quarterly report
2026-08-03	DEF 14A	Proxy statement
2026-07-30	8-K	Charter, bylaws or fiscal year change
2026-07-23	PRE 14A	Proxy statement
2026-07-14	13D/A	Beneficial ownership report (5%+ holder)
2026-06-26	424B3	Prospectus or prospectus supplement

Facts as of Oct 11, 2026, 08:13 AM UTC. Small caps move fast; check the latest filings.